New drug T320 targets tough tumors in early trial
Disease control
Not yet recruiting
This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…
Phase: PHASE1 • Sponsor: Nanolattix Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC